![]() ![]() 1įurther, PSA 50% (decrease ≥50% from baseline) response rates were 93% (77/83) in the combination arm, compared with 68% (54/79) for enzalutamide alone ( P <. ![]() Median radiographic PFS was 16 months with the combination therapy compared with 12 months for enzalutamide alone (HR, 0.67 95% CI, 0.44-1.01). Vincent’s Hospital in Sydney, Australia.ĭata from the study showed a median PSA-PFS of 13 months with the combination therapy compared with 7.8 months with enzalutamide alone (HR, 0.43 95% CI, 0.29-0.63 P =. Emmett is the director of theranostics and nuclear medicine at St. It provides strong evidence for an enhanced anti-cancer effect with the combination of enzalutamide and 177Lu-PSMA-617 based on the primary end point, PSA-PFS,” said Louise Emmett, MD, FRACP, during an oral presentation of the findings at the ESMO meeting. ![]() “This is the first randomized trial combining an androgen receptor signaling inhibitor, enzalutamide, with 177Lu-PSMA-617. Interim results from the phase 2 ENZA-p study (NCT04419402) show that adding 177Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) significantly enhances prostate-specific antigen progression-free survival (PSA-PFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), according to findings presented at the European Society of Medical Oncology (ESMO) Congress, Madrid, Spain. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |